The solution of cryoprecipitate is applied taking into account compatibility by blood groups of ABO. The container with the frozen cryoprecipitate is placed for thawing in a water bath at a temperature of 35-37 ° C. The drug dissolves completely at this temperature for 7 minutes. The resulting light yellow solution should not contain flakes and is used immediately after dissolution. The drug is administered intravenously, strontaneously, slowly using a syringe or a transfusion system with a disposable filter.
The dose of cryoprecipitate depends on the initial content of coagulation factor VIII in the blood of a patient with hemophilia,character and localization of bleeding, the degree of risk of surgical intervention, the presence of a specific inhibitor in the patient's blood that can neutralize the activity of factor VIII. The dose of cryoprecipitate is expressed in units of factor VIII activity.
To ensure effective hemostasis in the most frequent complications of hemophilia (hemarthrosis, renal, gingival and nasal bleeding), as well as when removing teeth, the content of factor VIII in plasma should not be less than 20% of activity; with intermuscular hematomas, gastrointestinal bleeding, fractures, trauma - not less than 40% of activity; at the majority of surgical interventions - not less than 70% of activity.
The number of doses of cryoprecipitate necessary to increase the concentration of factor VIII in the blood to a predetermined level is calculated taking into account that the administration of the preparation in an amount of 1 unit per kg of body weight of the patient increases the content of factor VIII in the blood by an average of 1%
X = Y x Z / 100, where
X - dose of cryoprecipitate;
U - body weight of the patient in kg;
Z- the necessary content of factor VIII in the patient's blood;
100 - the minimum content of factor VIII in units of activity in a single dose.
After complete hemostasis administering the drug to patients with hemophilia is performed at intervals of 12-24 hours and at a dose providing an increase factor VIII content of not less than 20% activity. Such treatment is continued for several days - until complete relief of inflammatory changes or visible reduction in the size of the hematoma.
In surgical interventions, the haemostatic dose of the drug is administered 30 minutes prior to surgery. With massive bleeding, the blood loss is compensated. The cryoprecipitate solution is reintroduced at the end of the operation at a dose equal to half the original dose. Within 3-5 days after the operation it is necessary to maintain the concentration of factor VIII in the patient's blood in the same range as during the operation. In the further postoperative period to maintain hemostasis, it is sufficient to increase the content of factor VIII to 20% of activity. The duration of the haemostatic therapy is, in most cases 7-14 days and depends on the nature of the surgery, bleeding localization features of reparative tissue.